James Patrick Allison - Publications

Affiliations: 
1985-1997 Molecular and Cell Biology University of California, Berkeley, Berkeley, CA 
 1997-2004 Rheumatology University of California, San Francisco, San Francisco, CA 
 2004-2012 Weill Cornell Medical College, New York, NY, United States 
 2006-2012 Memorial Sloan-Kettering Cancer Center, Rockville Centre, NY, United States 
 2012- Immunology M. D. Anderson Cancer Center, Houston, TX, United States 
Area:
Immunotherapy
Website:
https://faculty.mdanderson.org/profiles/james_allison.html

204 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Shi LZ, Goswami S, Fu T, Guan B, Chen J, Xiong L, Zhang J, Ng Tang D, Zhang X, Vence L, Blando J, Allison JP, Collazo R, Gao J, Sharma P. Blockade of CTLA-4 and PD-1 Enhances adoptive T-cell therapy efficacy in an ICOS mediated manner. Cancer Immunology Research. PMID 31466995 DOI: 10.1158/2326-6066.CIR-18-0873  1
2019 Vence L, Bucktrout SL, Fernandez Curbelo I, Blando J, Smith BM, Mahne AE, Lin JC, Park T, Pascua E, Chaparro-Riggers J, Subudhi SK, Borin Scutti J, Higa MG, Zhao H, Yadav SS, ... ... Allison JP, et al. Characterization and comparison of GITR expression in solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31358539 DOI: 10.1158/1078-0432.CCR-19-0289  1
2019 Kaseb AO, Vence L, Blando J, Yadav SS, Ikoma N, Carmagnani Pestana R, Vauthey JN, Allison JP, Sharma P. Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma. Cancer Immunology Research. PMID 31289040 DOI: 10.1158/2326-6066.CIR-18-0605  1
2019 Sharma A, Subudhi SK, Blando J, Vence L, Wargo J, Allison JP, Ribas A, Sharma P. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3 Regulatory T Cells (Tregs) in Human Cancers-Response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 25: 3469-3470. PMID 31160495 DOI: 10.1158/1078-0432.CCR-19-0402  1
2019 Wei SC, Sharma R, Anang NAS, Levine JH, Zhao Y, Mancuso JJ, Setty M, Sharma P, Wang J, Pe'er D, Allison JP. Negative Co-stimulation Constrains T Cell Differentiation by Imposing Boundaries on Possible Cell States. Immunity. PMID 30926234 DOI: 10.1016/j.immuni.2019.03.004  1
2019 Blando J, Sharma A, Higa MG, Zhao H, Vence L, Yadav SS, Kim J, Sepulveda AM, Sharp M, Maitra A, Wargo J, Tetzlaff M, Broaddus R, Katz MHG, Varadhachary GR, ... ... Allison JP, et al. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America. PMID 30635425 DOI: 10.1073/pnas.1811067116  1
2018 Williams P, Basu S, Garcia-Manero G, Hourigan CS, Oetjen KA, Cortes JE, Ravandi F, Jabbour EJ, Al-Hamal Z, Konopleva M, Ning J, Xiao L, Hidalgo Lopez J, Kornblau SM, Andreeff M, ... ... Allison JP, et al. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer. PMID 30500073 DOI: 10.1002/cncr.31896  1
2018 Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang ZD, Abu-Sbeih H, Sanchez CA, Chang CC, Parra ER, Francisco-Cruz A, Raju GS, Stroehlein JR, Campbell MT, ... ... Allison JP, et al. Author Correction: Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nature Medicine. PMID 30479380 DOI: 10.1038/s41591-018-0305-2  1
2018 Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang ZD, Abu-Sbeih H, Sanchez CA, Chang CC, Parra ER, Francisco-Cruz A, Raju GS, Stroehlein JR, Campbell MT, ... ... Allison JP, et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nature Medicine. PMID 30420754 DOI: 10.1038/s41591-018-0238-9  1
2018 Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, Konopleva M, Ravandi-Kashani F, Jabbour E, Kadia TM, Nogueras-Gonzalez GM, Ning J, Pemmaraju N, DiNardo CD, Andreeff M, ... ... Allison JP, et al. Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study. Cancer Discovery. PMID 30409776 DOI: 10.1158/2159-8290.CD-18-0774  1
2018 Sharma A, Subudhi SK, Blando J, Scutti J, Vence L, Wargo JA, Allison JP, Ribas A, Sharma P. Anti-CTLA-4 immunotherapy does not deplete FOXP3+ regulatory T cells (Tregs) in human cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30054281 DOI: 10.1158/1078-0432.CCR-18-0762  1
2018 Goswami S, Apostolou I, Zhang J, Skepner J, Anandhan S, Zhang X, Xiong L, Trojer P, Aparicio A, Subudhi SK, Allison JP, Zhao H, Sharma P. Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. The Journal of Clinical Investigation. PMID 29905573 DOI: 10.1172/JCI99760  1
2018 Ariyan CE, Brady MS, Siegelbaum RH, Hu J, Bello DM, Green J, Fisher C, Lefkowitz RA, Panageas KS, Pulitzer M, Vignali M, Emerson R, Tipton C, Robins H, Merghoub T, ... ... Allison JP, et al. Robust antitumor responses result from local chemotherapy and CTLA-4 blockade. Cancer Immunology Research. PMID 29339377 DOI: 10.1158/2326-6066.CIR-17-0356  1
2017 Khouri IF, Fernandez Curbelo I, Turturro F, Jabbour E, Milton DR, Bassett RL, Vence L, Allison JP, Gulbis AM, Sharma P. Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29246938 DOI: 10.1158/1078-0432.CCR-17-2777  1
2017 Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, ... ... Allison JP, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science (New York, N.Y.). PMID 29097493 DOI: 10.1126/science.aan4236  1
2017 Mbofung RM, McKenzie JA, Malu S, Zhang M, Peng W, Liu C, Kuiatse I, Tieu T, Williams L, Devi S, Ashkin E, Xu C, Huang L, Zhang M, Talukder AH, ... ... Allison JP, et al. HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes. Nature Communications. 8: 451. PMID 28878208 DOI: 10.1038/s41467-017-00449-z  1
2017 Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, Jiang H, Chen PL, Beird HC, Garber HR, Roh W, ... ... Allison JP, et al. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. Npj Genomic Medicine. 2. PMID 28819565 DOI: 10.1038/s41525-017-0013-8  1
2017 Wei SC, Levine JH, Cogdill AP, Zhao Y, Anang NAS, Andrews MC, Sharma P, Wang J, Wargo JA, Pe'er D, Allison JP. Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. Cell. PMID 28803728 DOI: 10.1016/j.cell.2017.07.024  1
2017 Reuben A, Gittelman RM, Gao J, Zhang J, Yusko E, Wu CJ, Emerson R, Zhang J, Tipton CM, Li J, Quek K, Gopalakrishnan V, Chen R, Vence L, Cascone T, ... ... Allison JP, et al. TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: an Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. Cancer Discovery. PMID 28733428 DOI: 10.1158/2159-8290.CD-17-0256  1
2017 Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, Troncoso P, Allison JP, Logothetis CJ, Wistuba II, Sepulveda MA, et al. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nature Medicine. PMID 28346412 DOI: 10.1038/nm.4308  1
2017 Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan V, Wang F, Cooper ZA, Reddy SM, Gumbs C, Little L, Chang Q, Chen WS, Wani K, ... ... Allison JP, et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Science Translational Medicine. 9. PMID 28251903 DOI: 10.1126/scitranslmed.aah3560  1
2017 Zamarin D, Holmgaard RB, Ricca J, Plitt T, Palese P, Sharma P, Merghoub T, Wolchok JD, Allison JP. Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. Nature Communications. 8: 14340. PMID 28194010 DOI: 10.1038/ncomms14340  1
2017 Haymaker CL, Kim D, Uemura M, Vence LM, Phillip A, McQuail N, Brown PD, Fernandez I, Hudgens CW, Creasy C, Hwu WJ, Sharma P, Tetzlaff MT, Allison JP, Hwu P, et al. Metastatic melanoma patient had complete response with clonal expansion after whole brain radiation and PD-1 blockade. Cancer Immunology Research. PMID 28062513 DOI: 10.1158/2326-6066.CIR-16-0223  1
2016 Wang X, Schoenhals JE, Li A, Valdecanas DR, Ye H, Zhang F, Tang C, Tang M, Liu CG, Liu X, Krishnan S, Allison JP, Sharma P, Hwu P, Komaki R, et al. Suppression of type I IFN signaling in tumors mediates resistance to anti-PD-1 treatment that can be overcome by radiotherapy. Cancer Research. PMID 27821490 DOI: 10.1158/0008-5472.CAN-15-3142  1
2016 Subudhi SK, Aparicio A, Gao J, Zurita AJ, Araujo JC, Logothetis CJ, Tahir SA, Korivi BR, Slack RS, Vence L, Emerson RO, Yusko E, Vignali M, Robins HS, Sun J, ... Allison JP, et al. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proceedings of the National Academy of Sciences of the United States of America. PMID 27698113 DOI: 10.1073/pnas.1611421113  1
2016 Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, Chen T, Roszik J, Bernatchez C, Woodman SE, Chen PL, Hwu P, Allison JP, Futreal A, Wargo JA, et al. Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell. PMID 27667683 DOI: 10.1016/j.cell.2016.08.069  1
2016 Uemura M, Trinh VA, Haymaker C, Jackson N, Kim DW, Allison JP, Sharma P, Vence L, Bernatchez C, Hwu P, Diab A. Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: a case report. Journal of Hematology & Oncology. 9: 81. PMID 27595932 DOI: 10.1186/s13045-016-0309-7  1
2016 Page DB, Yuan J, Redmond D, Wen YH, Durack JC, Emerson R, Solomon SB, Dong Z, Wong P, Comstock C, Diab A, Sung J, Maybody M, Morris EA, Brogi E, ... ... Allison JP, et al. Deep Sequencing of T-Cell Receptor DNA as a biomarker of clonally expanded TILs in breast cancer after immunotherapy. Cancer Immunology Research. PMID 27587469 DOI: 10.1158/2326-6066.CIR-16-0013  1
2016 Li CW, Lim SO, Xia W, Lee HH, Chan LC, Kuo CW, Khoo KH, Chang SS, Cha JH, Kim T, Hsu JL, Wu Y, Hsu JM, Yamaguchi H, Ding Q, ... ... Allison JP, et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nature Communications. 7: 12632. PMID 27572267 DOI: 10.1038/ncomms12632  1
2016 Shi LZ, Fu T, Guan B, Chen J, Blando JM, Allison JP, Xiong L, Subudhi SK, Gao J, Sharma P. Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy. Nature Communications. 7: 12335. PMID 27498556 DOI: 10.1038/ncomms12335  1
2016 Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, Petaccia De Macedo M, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, ... ... Allison JP, et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discovery. PMID 27301722 DOI: 10.1158/2159-8290.CD-15-1545  1
2016 Metzger TC, Long H, Potluri S, Pertel T, Bailey-Bucktrout SL, Lin JC, Fu T, Sharma P, Allison JP, Feldman RM. ICOS promotes the function of CD4+ effector T cells during anti-OX40 mediated tumor rejection. Cancer Research. PMID 27197182 DOI: 10.1158/0008-5472.CAN-15-3412  1
2016 Cooper ZA, Reuben A, Spencer CN, Prieto PA, Austin-Breneman JL, Jiang H, Haymaker C, Gopalakrishnan V, Tetzlaff MT, Frederick DT, Sullivan RJ, Amaria RN, Patel SP, Hwu P, Woodman SE, ... ... Allison JP, et al. Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. Oncoimmunology. 5: e1136044. PMID 27141370 DOI: 10.1080/2162402X.2015.1136044  1
2016 Mellman I, Hubbard-Lucey VM, Tontonoz MJ, Kalos MD, Chen DS, Allison JP, Drake CG, Levitsky H, Lonberg N, van der Burg SH, Fearon DT, Wherry EJ, Lowy I, Vonderheide RH, Hwu P. De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute. Cancer Immunology Research. 4: 279-88. PMID 27036972 DOI: 10.1158/2326-6066.CIR-16-0045  0.04
2015 Özdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, De Jesus-Acosta A, Sharma P, Heidari P, Mahmood U, Chin L, ... ... Allison JP, et al. Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival. Cancer Cell. 28: 831-833. PMID 28843279 DOI: 10.1016/j.ccell.2015.11.002  1
2015 Holmgaard RB, Zamarin D, Li Y, Gasmi B, Munn DH, Allison JP, Merghoub T, Wolchok JD. Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner. Cell Reports. PMID 26411680 DOI: 10.1016/j.celrep.2015.08.077  1
2015 Allison JP. Checkpoints. Cell. 162: 1202-5. PMID 26359978 DOI: 10.1016/j.cell.2015.08.047  1
2015 Bartkowiak T, Singh S, Yang G, Galvan G, Haria D, Ai M, Allison JP, Sastry KJ, Curran MA. Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine. Proceedings of the National Academy of Sciences of the United States of America. 112: E5290-9. PMID 26351680 DOI: 10.1073/pnas.1514418112  1
2015 Seyedin SN, Schoenhals JE, Lee DA, Cortez MA, Wang X, Niknam S, Tang C, Hong DS, Naing A, Sharma P, Allison JP, Chang JY, Gomez DR, Heymach JV, Komaki RU, et al. Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy. PMID 26310908 DOI: 10.2217/imt.15.65  1
2015 Lovisa S, LeBleu VS, Tampe B, Sugimoto H, Vadnagara K, Carstens JL, Wu CC, Hagos Y, Burckhardt BC, Pentcheva-Hoang T, Nischal H, Allison JP, Zeisberg M, Kalluri R. Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis. Nature Medicine. PMID 26236991 DOI: 10.1038/nm.3902  1
2015 Kreymborg K, Haak S, Murali R, Wei J, Waitz R, Gasteiger G, Savage PA, van den Brink MR, Allison JP. Ablation of B7-H3 but Not B7-H4 Results in Highly Increased Tumor Burden in a Murine Model of Spontaneous Prostate Cancer. Cancer Immunology Research. 3: 849-54. PMID 26122284 DOI: 10.1158/2326-6066.CIR-15-0100  1
2015 Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, Behrens C, Kadara H, Parra ER, Rodriguez Canales J, Zhang J, Giri U, Gudikote J, Cortez MA, Yang C, ... ... Allison JP, et al. Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities. Cancer Discovery. PMID 26069186 DOI: 10.1158/2159-8290.CD-14-1236  1
2015 Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 161: 205-14. PMID 25860605 DOI: 10.1016/j.cell.2015.03.030  1
2015 Sharma P, Allison JP. The future of immune checkpoint therapy. Science (New York, N.Y.). 348: 56-61. PMID 25838373 DOI: 10.1126/science.aaa8172  1
2015 Hannani D, Vétizou M, Enot D, Rusakiewicz S, Chaput N, Klatzmann D, Desbois M, Jacquelot N, Vimond N, Chouaib S, Mateus C, Allison JP, Ribas A, Wolchok JD, Yuan J, et al. Erratum: anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Research. 25: 399-400. PMID 25732764 DOI: 10.1038/cr.2015.28  1
2015 Pedicord VA, Cross JR, Montalvo-Ortiz W, Miller ML, Allison JP. Friends not foes: CTLA-4 blockade and mTOR inhibition cooperate during CD8+ T cell priming to promote memory formation and metabolic readiness. Journal of Immunology (Baltimore, Md. : 1950). 194: 2089-98. PMID 25624453 DOI: 10.4049/jimmunol.1402390  1
2015 Hannani D, Vétizou M, Enot D, Rusakiewicz S, Chaput N, Klatzmann D, Desbois M, Jacquelot N, Vimond N, Chouaib S, Mateus C, Allison JP, Ribas A, Wolchok JD, Yuan J, et al. Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Research. 25: 208-24. PMID 25582080 DOI: 10.1038/cr.2015.3  1
2014 Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, Mulder GE, Toebes M, Vesely MD, Lam SS, Korman AJ, ... Allison JP, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 515: 577-81. PMID 25428507 DOI: 10.1038/nature13988  1
2014 Tang C, Wang X, Soh H, Seyedin S, Cortez MA, Krishnan S, Massarelli E, Hong D, Naing A, Diab A, Gomez D, Ye H, Heymach J, Komaki R, Allison JP, et al. Combining radiation and immunotherapy: a new systemic therapy for solid tumors? Cancer Immunology Research. 2: 831-8. PMID 25187273 DOI: 10.1158/2326-6066.CIR-14-0069  1
2014 Pentcheva-Hoang T, Simpson TR, Montalvo-Ortiz W, Allison JP. Cytotoxic T lymphocyte antigen-4 blockade enhances antitumor immunity by stimulating melanoma-specific T-cell motility. Cancer Immunology Research. 2: 970-80. PMID 25038199 DOI: 10.1158/2326-6066.CIR-14-0104  1
2014 Özdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, De Jesus-Acosta A, Sharma P, Heidari P, Mahmood U, Chin L, ... ... Allison JP, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 25: 719-34. PMID 24856586 DOI: 10.1016/j.ccr.2014.04.005  1
2014 Fan X, Quezada SA, Sepulveda MA, Sharma P, Allison JP. Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. The Journal of Experimental Medicine. 211: 715-25. PMID 24687957 DOI: 10.1084/jem.20130590  1
2014 Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Science Translational Medicine. 6: 226ra32. PMID 24598590 DOI: 10.1126/scitranslmed.3008095  1
2014 Morris JC, Ramlogan-Steel CA, Yu P, Black BA, Mannan P, Allison JP, Waldmann TA, Steel JC. Vaccination with tumor cells expressing IL-15 and IL-15Rα inhibits murine breast and prostate cancer. Gene Therapy. 21: 393-401. PMID 24572789 DOI: 10.1038/gt.2014.10  1
2014 Page DB, Postow MA, Callahan MK, Allison JP, Wolchok JD. Immune modulation in cancer with antibodies. Annual Review of Medicine. 65: 185-202. PMID 24188664 DOI: 10.1146/annurev-med-092012-112807  1
2013 Ng Tang D, Shen Y, Sun J, Wen S, Wolchok JD, Yuan J, Allison JP, Sharma P. Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunology Research. 1: 229-34. PMID 24777852 DOI: 10.1158/2326-6066.CIR-13-0020  1
2013 Kitano S, Tsuji T, Liu C, Hirschhorn-Cymerman D, Kyi C, Mu Z, Allison JP, Gnjatic S, Yuan JD, Wolchok JD. Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients. Cancer Immunology Research. 1: 235-44. PMID 24396833 DOI: 10.1158/2326-6066.CIR-13-0068  1
2013 Reis BS, Jungbluth AA, Frosina D, Holz M, Ritter E, Nakayama E, Ishida T, Obata Y, Carver B, Scher H, Scardino PT, Slovin S, Subudhi SK, Reuter VE, Savage C, ... Allison JP, et al. Prostate cancer progression correlates with increased humoral immune response to a human endogenous retrovirus GAG protein. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 6112-25. PMID 24081977 DOI: 10.1158/1078-0432.CCR-12-3580  1
2013 Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, Roddie C, Henry JY, Yagita H, Wolchok JD, Peggs KS, Ravetch JV, Allison JP, Quezada SA. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. The Journal of Experimental Medicine. 210: 1695-710. PMID 23897981 DOI: 10.1084/jem.20130579  1
2013 Wolchok JD, Hodi FS, Weber JS, Allison JP, Urba WJ, Robert C, O'Day SJ, Hoos A, Humphrey R, Berman DM, Lonberg N, Korman AJ. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Annals of the New York Academy of Sciences. 1291: 1-13. PMID 23772560 DOI: 10.1111/nyas.12180  1
2013 Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. The Journal of Experimental Medicine. 210: 1389-402. PMID 23752227 DOI: 10.1084/jem.20130066  1
2013 Gyorki DE, Yuan J, Mu Z, Zaidi B, Pulitzer M, Busam K, Brady MS, Coit DG, Allison JP, Wolchok JD, Ariyan CE. Immunological insights from patients undergoing surgery on ipilimumab for metastatic melanoma. Annals of Surgical Oncology. 20: 3106-11. PMID 23681603 DOI: 10.1245/s10434-013-2999-1  1
2013 Curran MA, Geiger TL, Montalvo W, Kim M, Reiner SL, Al-Shamkhani A, Sun JC, Allison JP. Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin. The Journal of Experimental Medicine. 210: 743-55. PMID 23547098 DOI: 10.1084/jem.20121190  1
2013 Malchow S, Leventhal DS, Nishi S, Fischer BI, Shen L, Paner GP, Amit AS, Kang C, Geddes JE, Allison JP, Socci ND, Savage PA. Aire-dependent thymic development of tumor-associated regulatory T cells. Science (New York, N.Y.). 339: 1219-24. PMID 23471412 DOI: 10.1126/science.1233913  1
2013 Corse E, Gottschalk RA, Park JS, Sepulveda MA, Loke P, Sullivan TJ, Johnson LK, Allison JP. Cutting edge: chronic inflammatory liver disease in mice expressing a CD28-specific ligand. Journal of Immunology (Baltimore, Md. : 1950). 190: 526-30. PMID 23248264 DOI: 10.4049/jimmunol.1202621  1
2012 Galon J, Pagès F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, ... ... Allison JP, et al. Cancer classification using the Immunoscore: a worldwide task force. Journal of Translational Medicine. 10: 205. PMID 23034130 DOI: 10.1186/1479-5876-10-205  1
2012 Mineharu Y, Muhammad AK, Yagiz K, Candolfi M, Kroeger KM, Xiong W, Puntel M, Liu C, Levy E, Lugo C, Kocharian A, Allison JP, Curran MA, Lowenstein PR, Castro MG. Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer model. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 9: 827-43. PMID 22996231 DOI: 10.1007/s13311-012-0144-7  1
2012 Lee JS, Scandiuzzi L, Ray A, Wei J, Hofmeyer KA, Abadi YM, Loke P, Lin J, Yuan J, Serreze DV, Allison JP, Zang X. B7x in the periphery abrogates pancreas-specific damage mediated by self-reactive CD8 T cells. Journal of Immunology (Baltimore, Md. : 1950). 189: 4165-74. PMID 22972920 DOI: 10.4049/jimmunol.1201241  1
2012 Scott AM, Allison JP, Wolchok JD. Monoclonal antibodies in cancer therapy. Cancer Immunity. 12: 14. PMID 22896759  1
2012 Srivastava PK, Cerundolo V, Knuth A, Allison JP. An open invitation to the cancer immunology community. Cancer Immunity. 12: 1. PMID 22896746  0.01
2012 Waitz R, Fassò M, Allison JP. CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection. Oncoimmunology. 1: 544-546. PMID 22754781 DOI: 10.4161/onci.19442  1
2012 Corse E, Allison JP. Cutting edge: CTLA-4 on effector T cells inhibits in trans. Journal of Immunology (Baltimore, Md. : 1950). 189: 1123-7. PMID 22753941 DOI: 10.4049/jimmunol.1200695  0.68
2012 Zhang M, Ju W, Yao Z, Yu P, Wei BR, Simpson RM, Waitz R, Fassò M, Allison JP, Waldmann TA. Augmented IL-15Rα expression by CD40 activation is critical in synergistic CD8 T cell-mediated antitumor activity of anti-CD40 antibody with IL-15 in TRAMP-C2 tumors in mice. Journal of Immunology (Baltimore, Md. : 1950). 188: 6156-64. PMID 22593619 DOI: 10.4049/jimmunol.1102604  1
2012 Jenq RR, Curran MA, Goldberg GL, Liu C, Allison JP, van den Brink MR. Repertoire enhancement with adoptively transferred female lymphocytes controls the growth of pre-implanted murine prostate cancer. Plos One. 7: e35222. PMID 22493742 DOI: 10.1371/journal.pone.0035222  1
2012 Yu P, Steel JC, Zhang M, Morris JC, Waitz R, Fasso M, Allison JP, Waldmann TA. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model. Proceedings of the National Academy of Sciences of the United States of America. 109: 6187-92. PMID 22474386 DOI: 10.1073/pnas.1203479109  1
2012 Curran MA, Callahan MK, Subudhi SK, Allison JP. Response to "Ipilimumab (Yervoy) and the TGN1412 catastrophe". Immunobiology. 217: 590-2. PMID 22459268 DOI: 10.1016/j.imbio.2011.11.001  1
2012 Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E, Sedrak C, Jungbluth AA, Chua R, Yang AS, Roman RA, ... ... Allison JP, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. The New England Journal of Medicine. 366: 925-31. PMID 22397654 DOI: 10.1056/NEJMoa1112824  1
2012 Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, Arthur CD, White JM, Chen YS, Shea LK, Hundal J, Wendl MC, Demeter R, Wylie T, Allison JP, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature. 482: 400-4. PMID 22318521 DOI: 10.1038/nature10755  1
2012 Sharma P, Allison JP. Retrospective. Lloyd J. Old (1933-2011). Science (New York, N.Y.). 335: 49. PMID 22223799 DOI: 10.1126/science.1217940  1
2012 Gottschalk RA, Hathorn MM, Beuneu H, Corse E, Dustin ML, Altan-Bonnet G, Allison JP. Distinct influences of peptide-MHC quality and quantity on in vivo T-cell responses. Proceedings of the National Academy of Sciences of the United States of America. 109: 881-6. PMID 22223661 DOI: 10.1073/pnas.1119763109  0.68
2012 Gottschalk RA, Corse E, Allison JP. Expression of Helios in peripherally induced Foxp3+ regulatory T cells. Journal of Immunology (Baltimore, Md. : 1950). 188: 976-80. PMID 22198953 DOI: 10.4049/jimmunol.1102964  0.68
2012 Waitz R, Solomon SB, Petre EN, Trumble AE, Fassò M, Norton L, Allison JP. Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Research. 72: 430-9. PMID 22108823 DOI: 10.1158/0008-5472.CAN-11-1782  1
2011 Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, et al. Defining the critical hurdles in cancer immunotherapy. Journal of Translational Medicine. 9: 214. PMID 22168571 DOI: 10.1186/1479-5876-9-214  1
2011 Allison JP, Benoist C, Chervonsky AV. Nobels: Toll pioneers deserve recognition. Nature. 479: 178. PMID 22071753 DOI: 10.1038/479178a  1
2011 Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nature Reviews. Cancer. 11: 805-12. PMID 22020206 DOI: 10.1038/nrc3153  1
2011 Yuan J, Adamow M, Ginsberg BA, Rasalan TS, Ritter E, Gallardo HF, Xu Y, Pogoriler E, Terzulli SL, Kuk D, Panageas KS, Ritter G, Sznol M, Halaban R, Jungbluth AA, ... Allison JP, et al. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proceedings of the National Academy of Sciences of the United States of America. 108: 16723-8. PMID 21933959 DOI: 10.1073/pnas.1110814108  1
2011 Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H, Sorenson EC, Popow R, Ariyan C, Rossi F, Besmer P, Guo T, Antonescu CR, Taguchi T, Yuan J, ... ... Allison JP, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nature Medicine. 17: 1094-100. PMID 21873989 DOI: 10.1038/nm.2438  1
2011 Donkor MK, Sarkar A, Savage PA, Franklin RA, Johnson LK, Jungbluth AA, Allison JP, Li MO. T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-β1 cytokine. Immunity. 35: 123-34. PMID 21757379 DOI: 10.1016/j.immuni.2011.04.019  1
2011 Curran MA, Kim M, Montalvo W, Al-Shamkhani A, Allison JP. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. Plos One. 6: e19499. PMID 21559358 DOI: 10.1371/journal.pone.0019499  1
2011 Corse E, Gottschalk RA, Allison JP. Strength of TCR-peptide/MHC interactions and in vivo T cell responses. Journal of Immunology (Baltimore, Md. : 1950). 186: 5039-45. PMID 21505216 DOI: 10.4049/jimmunol.1003650  0.68
2011 Quezada SA, Peggs KS, Simpson TR, Allison JP. Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunological Reviews. 241: 104-18. PMID 21488893 DOI: 10.1111/j.1600-065X.2011.01007.x  1
2011 Yuan J, Ginsberg B, Page D, Li Y, Rasalan T, Gallardo HF, Xu Y, Adams S, Bhardwaj N, Busam K, Old LJ, Allison JP, Jungbluth A, Wolchok JD. CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases. Cancer Immunology, Immunotherapy : Cii. 60: 1137-46. PMID 21465316 DOI: 10.1007/s00262-011-1011-9  1
2011 Pedicord VA, Montalvo W, Leiner IM, Allison JP. Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance. Proceedings of the National Academy of Sciences of the United States of America. 108: 266-71. PMID 21173239 DOI: 10.1073/pnas.1016791108  0.36
2010 Callahan MK, Wolchok JD, Allison JP. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Seminars in Oncology. 37: 473-84. PMID 21074063 DOI: 10.1053/j.seminoncol.2010.09.001  1
2010 Corse E, Gottschalk RA, Krogsgaard M, Allison JP. Attenuated T cell responses to a high-potency ligand in vivo. Plos Biology. 8. PMID 20856903 DOI: 10.1371/journal.pbio.1000481  0.68
2010 Gottschalk RA, Corse E, Allison JP. TCR ligand density and affinity determine peripheral induction of Foxp3 in vivo. The Journal of Experimental Medicine. 207: 1701-11. PMID 20660617 DOI: 10.1084/jem.20091999  0.68
2010 Zang X, Sullivan PS, Soslow RA, Waitz R, Reuter VE, Wilton A, Thaler HT, Arul M, Slovin SF, Wei J, Spriggs DR, Dupont J, Allison JP. Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 23: 1104-12. PMID 20495537 DOI: 10.1038/modpathol.2010.95  1
2010 Carthon BC, Wolchok JD, Yuan J, Kamat A, Ng Tang DS, Sun J, Ku G, Troncoso P, Logothetis CJ, Allison JP, Sharma P. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 2861-71. PMID 20460488 DOI: 10.1158/1078-0432.CCR-10-0569  1
2010 Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proceedings of the National Academy of Sciences of the United States of America. 107: 4275-80. PMID 20160101 DOI: 10.1073/pnas.0915174107  1
2010 Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, Blasberg R, Yagita H, Muranski P, Antony PA, Restifo NP, Allison JP. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. The Journal of Experimental Medicine. 207: 637-50. PMID 20156971 DOI: 10.1084/jem.20091918  1
2010 Ku GY, Yuan J, Page DB, Schroeder SE, Panageas KS, Carvajal RD, Chapman PB, Schwartz GK, Allison JP, Wolchok JD. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer. 116: 1767-75. PMID 20143434 DOI: 10.1002/cncr.24951  1
2010 Simpson TR, Quezada SA, Allison JP. Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS). Current Opinion in Immunology. 22: 326-32. PMID 20116985 DOI: 10.1016/j.coi.2010.01.001  1
2010 Yuan J, Page DB, Ku GY, Li Y, Mu Z, Ariyan C, Gallardo HF, Roman RA, Heine AI, Terzulli SL, Ritter E, Gnjatic S, Ritter G, Jungbluth AA, Allison JP, et al. Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy. Cancer Immunity. 10: 1. PMID 20052966  1
2009 Thompson RH, Kwon ED, Allison JP. Inhibitors of B7-CD28 costimulation in urologic malignancies Immunotherapy. 1: 129-139. PMID 20445772 DOI: 10.2217/1750743X.1.1.129  1
2009 Lin Y, Gallardo HF, Ku GY, Li H, Manukian G, Rasalan TS, Xu Y, Terzulli SL, Old LJ, Allison JP, Houghton AN, Wolchok JD, Yuan J. Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses. Cytotherapy. 11: 912-22. PMID 19903103 DOI: 10.3109/14653240903136987  1
2009 Curran MA, Allison JP. Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors. Cancer Research. 69: 7747-55. PMID 19738077 DOI: 10.1158/0008-5472.CAN-08-3289  1
2009 Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 5323-37. PMID 19723653 DOI: 10.1158/1078-0432.CCR-09-0737  1
2009 Peggs KS, Quezada SA, Allison JP. Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clinical and Experimental Immunology. 157: 9-19. PMID 19659765 DOI: 10.1111/j.1365-2249.2009.03912.x  1
2009 Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. The Journal of Experimental Medicine. 206: 1717-25. PMID 19581407 DOI: 10.1084/jem.20082492  1
2009 Pentcheva-Hoang T, Corse E, Allison JP. Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections. Immunological Reviews. 229: 67-87. PMID 19426215 DOI: 10.1111/j.1600-065X.2009.00763.x  0.68
2008 Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, Ritter E, Ku GY, Jungbluth AA, Segal NH, Rasalan TS, Manukian G, Xu Y, Roman RA, Terzulli SL, Heywood M, ... ... Allison JP, et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proceedings of the National Academy of Sciences of the United States of America. 105: 20410-5. PMID 19074257 DOI: 10.1073/pnas.0810114105  1
2008 Peggs KS, Quezada SA, Allison JP. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunological Reviews. 224: 141-65. PMID 18759925 DOI: 10.1111/j.1600-065X.2008.00649.x  1
2008 Quezada SA, Peggs KS, Simpson TR, Shen Y, Littman DR, Allison JP. Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. The Journal of Experimental Medicine. 205: 2125-38. PMID 18725522 DOI: 10.1084/jem.20080099  1
2008 Fassò M, Waitz R, Hou Y, Rim T, Greenberg NM, Shastri N, Fong L, Allison JP. SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade. Proceedings of the National Academy of Sciences of the United States of America. 105: 3509-14. PMID 18303116 DOI: 10.1073/pnas.0712269105  1
2008 Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, Macrae S, Nelson M, Canning C, Lowy I, Korman A, Lautz D, Russell S, Jaklitsch MT, Ramaiya N, ... ... Allison JP, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proceedings of the National Academy of Sciences of the United States of America. 105: 3005-10. PMID 18287062 DOI: 10.1073/pnas.0712237105  1
2008 Segal NH, Parsons DW, Peggs KS, Velculescu V, Kinzler KW, Vogelstein B, Allison JP. Epitope landscape in breast and colorectal cancer Cancer Research. 68: 889-892. PMID 18245491 DOI: 10.1158/0008-5472.CAN-07-3095  1
2008 Simmons AD, Moskalenko M, Creson J, Fang J, Yi S, VanRoey MJ, Allison JP, Jooss K. Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity Cancer Immunology, Immunotherapy. 57: 1263-1270. PMID 18236040 DOI: 10.1007/s00262-008-0451-3  1
2008 Savage PA, Vosseller K, Kang C, Larimore K, Riedel E, Wojnoonski K, Jungbluth AA, Allison JP. Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8+ T lymphocytes. Science (New York, N.Y.). 319: 215-20. PMID 18187659 DOI: 10.1126/science.1148886  1
2007 Zang X, Thompson RH, Al-Ahmadie HA, Serio AM, Reuter VE, Eastham JA, Scardino PT, Sharma P, Allison JP. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proceedings of the National Academy of Sciences of the United States of America. 104: 19458-63. PMID 18042703 DOI: 10.1073/pnas.0709802104  1
2007 Pentcheva-Hoang T, Chen L, Pardoll DM, Allison JP. Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availability. Proceedings of the National Academy of Sciences of the United States of America. 104: 17765-70. PMID 17968013 DOI: 10.1073/pnas.0708767104  0.4
2007 Zang X, Allison JP. The B7 family and cancer therapy: costimulation and coinhibition. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 5271-9. PMID 17875755 DOI: 10.1158/1078-0432.CCR-07-1030  1
2007 Peggs KS, Segal NH, Allison JP. Targeting immunosupportive cancer therapies: accentuate the positive, eliminate the negative. Cancer Cell. 12: 192-9. PMID 17785201 DOI: 10.1016/j.ccr.2007.08.023  0.4
2007 Fecci PE, Ochiai H, Mitchell DA, Grossi PM, Sweeney AE, Archer GE, Cummings T, Allison JP, Bigner DD, Sampson JH. Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 2158-67. PMID 17404100 DOI: 10.1158/1078-0432.CCR-06-2070  1
2007 Sharma P, Old LJ, Allison JP. Immunotherapeutic strategies for high-risk bladder cancer. Seminars in Oncology. 34: 165-72. PMID 17382800 DOI: 10.1053/j.seminoncol.2006.12.004  1
2007 Cao E, Zang X, Ramagopal UA, Mukhopadhaya A, Fedorov A, Fedorov E, Zencheck WD, Lary JW, Cole JL, Deng H, Xiao H, Dilorenzo TP, Allison JP, Nathenson SG, Almo SC. T cell immunoglobulin mucin-3 crystal structure reveals a galectin-9-independent ligand-binding surface. Immunity. 26: 311-21. PMID 17363302 DOI: 10.1016/j.immuni.2007.01.016  1
2006 Zang X, Allison JP. To be or not to be B7. The Journal of Clinical Investigation. 116: 2590-3. PMID 17016555 DOI: 10.1172/JCI30103  1
2006 Zang X, Loke P, Kim J, Wojnoonski K, Kusdra L, Allison JP. A genetic library screen for signaling proteins that interact with phosphorylated T cell costimulatory receptors. Genomics. 88: 841-5. PMID 17014982 DOI: 10.1016/j.ygeno.2006.08.012  1
2006 Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. The Journal of Clinical Investigation. 116: 1935-45. PMID 16778987 DOI: 10.1172/JCI27745  1
2006 Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Advances in Immunology. 90: 297-339. PMID 16730267 DOI: 10.1016/S0065-2776(06)90008-X  1
2006 Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Current Opinion in Immunology. 18: 206-13. PMID 16464564 DOI: 10.1016/j.coi.2006.01.011  1
2006 Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 439: 682-7. PMID 16382236 DOI: 10.1038/nature04444  1
2005 Puré E, Allison JP, Schreiber RD. Breaking down the barriers to cancer immunotherapy. Nature Immunology. 6: 1207-10. PMID 16369561 DOI: 10.1038/ni1205-1207  1
2005 Peggs KS, Allison JP. Co-stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamily. British Journal of Haematology. 130: 809-24. PMID 16156851 DOI: 10.1111/j.1365-2141.2005.05627.x  0.4
2005 Loke P, Zang X, Hsuan L, Waitz R, Locksley RM, Allen JE, Allison JP. Inducible costimulator is required for type 2 antibody isotype switching but not T helper cell type 2 responses in chronic nematode infection. Proceedings of the National Academy of Sciences of the United States of America. 102: 9872-7. PMID 15994233 DOI: 10.1073/pnas.0503961102  1
2005 Demaria S, Kawashima N, Yang AM, Devitt ML, Babb JS, Allison JP, Formenti SC. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 728-34. PMID 15701862  1
2005 Ehrlich LI, Ogasawara K, Hamerman JA, Takaki R, Zingoni A, Allison JP, Lanier LL. Engagement of NKG2D by cognate ligand or antibody alone is insufficient to mediate costimulation of human and mouse CD8+ T cells. Journal of Immunology (Baltimore, Md. : 1950). 174: 1922-31. PMID 15699119  1
2004 Roden AC, Moser MT, Tri SD, Mercader M, Kuntz SM, Dong H, Hurwitz AA, McKean DJ, Celis E, Leibovich BC, Allison JP, Kwon ED. Augmentation of T cell levels and responses induced by androgen deprivation. Journal of Immunology (Baltimore, Md. : 1950). 173: 6098-108. PMID 15528346  1
2004 Pentcheva-Hoang T, Egen JG, Wojnoonski K, Allison JP. B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity. 21: 401-13. PMID 15357951 DOI: 10.1016/j.immuni.2004.06.017  0.64
2004 Gregor PD, Wolchok JD, Ferrone CR, Buchinshky H, Guevara-Patiño JA, Perales MA, Mortazavi F, Bacich D, Heston W, Latouche JB, Sadelain M, Allison JP, Scher HI, Houghton AN. CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine. 22: 1700-8. PMID 15068853 DOI: 10.1016/j.vaccine.2003.10.048  1
2003 Zang X, Loke P, Kim J, Murphy K, Waitz R, Allison JP. B7x: a widely expressed B7 family member that inhibits T cell activation. Proceedings of the National Academy of Sciences of the United States of America. 100: 10388-92. PMID 12920180 DOI: 10.1073/pnas.1434299100  1
2003 Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, Duray PH, Steinberg SM, Allison JP, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proceedings of the National Academy of Sciences of the United States of America. 100: 8372-7. PMID 12826605 DOI: 10.1073/pnas.1533209100  1
2003 Hurwitz AA, Yanover P, Markowitz M, Allison JP, Kwon ED. Prostate cancer: advances in immunotherapy. Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy. 17: 131-8. PMID 12641491 DOI: 10.2165/00063030-200317020-00005  1
2002 Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nature Immunology. 3: 611-8. PMID 12087419 DOI: 10.1038/ni0702-611  0.64
2002 Hurwitz AA, Sullivan TJ, Sobel RA, Allison JP. Cytotoxic T lymphocyte antigen-4 (CTLA-4) limits the expansion of encephalitogenic T cells in experimental autoimmune encephalomyelitis (EAE)-resistant BALB/c mice. Proceedings of the National Academy of Sciences of the United States of America. 99: 3013-7. PMID 11867713 DOI: 10.1073/pnas.042684699  1
2002 Egen JG, Allison JP. Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity. 16: 23-35. PMID 11825563  0.64
2001 Hurwitz AA, Foster BA, Allison JP, Greenberg NM, Kwon ED. The TRAMP mouse as a model for prostate cancer. Current Protocols in Immunology / Edited by John E. Coligan ... [Et Al.]. Unit 20.5. PMID 18432778 DOI: 10.1002/0471142735.im2005s45  1
2001 Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, Toes RE, Offringa R, Melief CJ. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. The Journal of Experimental Medicine. 194: 823-32. PMID 11560997 DOI: 10.1084/jem.194.6.823  1
2001 van Elsas A, Sutmuller RP, Hurwitz AA, Ziskin J, Villasenor J, Medema JP, Overwijk WW, Restifo NP, Melief CJ, Offringa R, Allison JP. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. The Journal of Experimental Medicine. 194: 481-9. PMID 11514604 DOI: 10.1084/jem.194.4.481  1
2001 Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy Annual Review of Immunology. 19: 565-594. PMID 11244047 DOI: 10.1146/annurev.immunol.19.1.565  1
2001 Sullivan TJ, Letterio JJ, Van Elsas A, Mamura M, Van Amelsfort J, Sharpe S, Metzler B, Chambers CA, Allison JP. Lack of a role for transforming growth factor-β in cytotoxic T lymphocyte antigen-4-mediated inhibition of T cell activation Proceedings of the National Academy of Sciences of the United States of America. 98: 2587-2592. PMID 11226283 DOI: 10.1073/pnas.051632398  1
2000 Kuhns MS, Epshteyn V, Sobel RA, Allison JP. Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates the size, reactivity, and function of a primed pool of CD4+ T cells. Proceedings of the National Academy of Sciences of the United States of America. 97: 12711-6. PMID 11050166 DOI: 10.1073/pnas.220423597  1
2000 Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Greenberg NM, Burg MB, Allison JP. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Research. 60: 2444-8. PMID 10811122  1
2000 Yu X, Fournier S, Allison JP, Sharpe AH, Hodes RJ. The role of B7 costimulation in CD4/CD8 T cell homeostasis Journal of Immunology. 164: 3543-3553. PMID 10725709  1
1999 Chambers CA, Allison JP. CTLA-4 - The costimulatory molecule that doesn't: Regulation of T-cell responses by inhibition Cold Spring Harbor Symposia On Quantitative Biology. 64: 303-312. PMID 11232300  1
1999 van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. The Journal of Experimental Medicine. 190: 355-66. PMID 10430624 DOI: 10.1084/jem.190.3.355  1
1999 Chambers CA, Kuhns MS, Allison JP. Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates primary and secondary peptide-specific CD4+ T cell responses Proceedings of the National Academy of Sciences of the United States of America. 96: 8603-8608. PMID 10411922 DOI: 10.1073/pnas.96.15.8603  1
1999 Brunner MC, Chambers CA, Chan FK, Hanke J, Winoto A, Allison JP. CTLA-4-Mediated inhibition of early events of T cell proliferation. Journal of Immunology (Baltimore, Md. : 1950). 162: 5813-20. PMID 10229815  1
1999 Chambers CA, Allison JP. Costimulatory regulation of T cell function Current Opinion in Cell Biology. 11: 203-210. PMID 10209159 DOI: 10.1016/S0955-0674(99)80027-1  1
1998 Chambers CA, Sullivan TJ, Truong T, Allison JP. Secondary but not primary T cell responses are enhanced in CTLA-4-deficient CD8+ T cells European Journal of Immunology. 28: 3137-3143. PMID 9808182 DOI: 10.1002/(SICI)1521-4141(199810)28:10<3137::AID-IMMU3137>3.0.CO;2-X  1
1998 Allison JP, Chambers C, Hurwitz A, Sullivan T, Boitel B, Fournier S, Brunner M, Krummel M. A role for CTLA-4-mediated inhibitory signals in peripheral T cell tolerance? Novartis Foundation Symposium. 215: 92-8; discussion 98-. PMID 9760573  1
1998 Hurwitz AA, Yu TF, Leach DR, Allison JP. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proceedings of the National Academy of Sciences of the United States of America. 95: 10067-71. PMID 9707601 DOI: 10.1073/pnas.95.17.10067  1
1998 Hurwitz AA, Townsend SE, Yu TF, Wallin JA, Allison JP. Enhancement of the anti-tumor immune response using a combination of interferon-gamma and B7 expression in an experimental mammary carcinoma. International Journal of Cancer. Journal International Du Cancer. 77: 107-13. PMID 9639401 DOI: 10.1002/(SICI)1097-0215(19980703)77:1<107::AID-IJC17>3.0.CO;2-B  1
1997 Chambers CA, Cado D, Truong T, Allison JP. Thymocyte development is normal in CTLA-4-deficient mice Proceedings of the National Academy of Sciences of the United States of America. 94: 9296-9301. PMID 9256476 DOI: 10.1073/pnas.94.17.9296  1
1997 Liao XC, Fournier S, Killeen N, Weiss A, Allison JP, Littman DR. Itk negatively regulates induction of T cell proliferation by CD28 costimulation Journal of Experimental Medicine. 186: 221-228. PMID 9221751 DOI: 10.1084/jem.186.2.221  1
1997 Chambers CA, Allison JP. Co-stimulation in T cell responses Current Opinion in Immunology. 9: 396-404. PMID 9203422 DOI: 10.1016/S0952-7915(97)80087-8  1
1997 Hurwitz AA, Sullivan TJ, Krummel MF, Sobel RA, Allison JP. Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis. Journal of Neuroimmunology. 73: 57-62. PMID 9058759 DOI: 10.1016/S0165-5728(96)00168-3  1
1996 Chambers CA, Krummel MF, Boitel B, Hurwitz A, Sullivan TJ, Fournier S, Cassell D, Brunner M, Allison JP. The role of CTLA-4 in the regulation and initiation of T-Cell responses Immunological Reviews. 27-46. PMID 9010718  1
1996 Chambers CA, Allison JP. The role of tyrosine phosphorylation and PTP-1C in CTLA-4 signal transduction European Journal of Immunology. 26: 3224-3229. PMID 8977326  1
1995 Zhang Y, Cado D, Asarnow DM, Komori T, Alt FW, Raulet DH, Allison JP. The role of short homology repeats and TdT in generation of the invariant gamma delta antigen receptor repertoire in the fetal thymus. Immunity. 3: 439-47. PMID 7584135 DOI: 10.1016/1074-7613(95)90173-6  1
1995 Robey E, Allison JP. T-cell activation: integration of signals from the antigen receptor and costimulatory molecules Immunology Today. 16: 306-310. PMID 7576059 DOI: 10.1016/0167-5699(95)80140-5  1
1994 Holsti MA, McArthur J, Allison JP, Raulet DH. Role of IL-6, IL-1, and CD28 signaling in responses of mouse CD4+ T cells to immobilized anti-TCR monoclonal antibody Journal of Immunology. 152: 1618-1628. PMID 7907103  1
1994 Townsend SE, Su FW, Atherton JM, Allison JP. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Research. 54: 6477-83. PMID 7527298  1
1994 Allison JP. CD28-B7 interactions in T-cell activation Current Opinion in Immunology. 6: 414-419. PMID 7522466 DOI: 10.1016/0952-7915(94)90120-1  1
1993 Leclercq G, Plum J, Nandi D, De Smedt M, Allison JP. Intrathymic differentiation of V gamma 3 T cells. The Journal of Experimental Medicine. 178: 309-15. PMID 8315386  1
1993 Townsend SE, Allison JP. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science (New York, N.Y.). 259: 368-70. PMID 7678351  1
1992 Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones Nature. 356: 607-609. PMID 1313950  1
1991 Glaichenhaus N, Davis C, Bornschlegel K, Allison JP, Shastri N. A novel strategy for the generation of T cell lines lacking expression of endogenous α- and/or β-chain T cell receptor genes Journal of Immunology. 146: 2095-2101. PMID 1826016  1
1990 Allison JP, Raulet DH. The immunobiology of γδ+ T cells Seminars in Immunology. 2: 59-65. PMID 2151798  1
1989 Havran WL, Poenie M, Tigelaar RE, Tsien RY, Allison JP. Phenotypic and functional analysis of gamma delta T cell receptor-positive murine dendritic epidermal clones. Journal of Immunology (Baltimore, Md. : 1950). 142: 1422-8. PMID 2783942  1
1989 Duplay P, Lancki D, Allison JP. Distribution and ontogeny of CD2 expression by murine T cells Journal of Immunology. 142: 2998-3005. PMID 2565352  1
1989 Asarnow DM, Goodman T, LeFrancois L, Allison JP. Distinct antigen receptor repertoires of two classes of murine epithelium-associated T cells Nature. 341: 60-62. PMID 2528075  1
1989 Marusic-Galesic S, Saito T, Tentori L, Zuniga-Pflucker J, Raulet DH, Allison JP, Kruisbeek AM. A novel γδ T cell receptor for antigen adds limited diversity to the γδ repertoire in adult thymus Journal of Immunology. 142: 28-34. PMID 2521236  1
1988 Allison JP, Hayran WL, Asarnow D, Tigelaar RE, Tucker PW, Bonyhadi M. γδ Antigen receptors of Thy-1 + dendritic epidermal cells: Implications for thymic differentiation Immunologic Research. 7: 292-302. PMID 2906352 DOI: 10.1007/BF02935534  1
1988 Asarnow DM, Kuziel WA, Bonyhad M, Tigelaar RE, Tucker PW, Allison JP. Limited diversity of γδ antigen receptor genes of thy-1+ dendritic epidermal cells Cell. 55: 837-847. PMID 2847872 DOI: 10.1016/0092-8674(88)90139-0  1
1987 Bonyhadi M, Weiss A, Tucker PW, Tigelaar RE, Allison JP. Delta is the Cx-gene product in the γ/δ antigen receptor of dendritic epidermal cells Nature. 330: 574-576. PMID 3500417  1
1987 Havran WL, Poenie M, Kimura J, Tsien R, Weiss A, Allison JP. Expression and function of the CD3-antigen receptor on murine CD4+8+ thymocytes. Nature. 330: 170-3. PMID 2959867 DOI: 10.1038/330170a0  1
1987 Allison JP, Lanier LL. Structure, function, and serology of the T-cell antigen receptor complex Annual Review of Immunology. 5: 503-540. PMID 2439105  1
1985 Allison JP, Lanier LL. Identification of antigen receptor-associated structures on murine T cells Nature. 314: 107-109. PMID 2579338 DOI: 10.1038/314107a0  1
1983 Lanier LL, Richie ER, Howell AL, Allison JP. Expression of Ly-1 and Ly-2 on a spontaneous AKR B-cell lymphoma Immunogenetics. 17: 655-659. PMID 6602763 DOI: 10.1007/BF00366133  1
1979 Callahan GN, Allison JP, Pellegrino MA, Reisfeld RA. Physical association of histocompatibility antigens and tumor-associated antigens on the surface of murine lymphoma cells. Journal of Immunology (Baltimore, Md. : 1950). 122: 70-4. PMID 762424  1
1978 Allison JP, Belvedere M, Reisfeld RA, Pellegrino MA, Ferrone S. Serologic and immunochemical characterization of HLA-A9 xenoantisera. Journal of Immunology (Baltimore, Md. : 1950). 121: 579-85. PMID 681750  1
1978 Allison JP, Ferrone S, Walker LE, Pellegrino MA, Silver J, Reisfeld RA. Partial amino acid sequence of HLA‐A9 antigen purified with a specific xenoantiserum Transplantation. 26: 451-453. PMID 569916  1
1978 Allison JP, Walker LE, Russell WA, Pellegrino MA, Ferrone S, Reisfeld RA, Frelinger JA, Silver J. Murine Ia and human DR antigens. Homology of amino-terminal sequences Proceedings of the National Academy of Sciences of the United States of America. 75: 3953-3956. PMID 99745  1
1978 Callahan GN, Allison JP. H-2 antigens on a murine lymphoma are associated with additional proteins. Nature. 271: 165-7. PMID 74802  1
1977 Allison JP, Ferrone S, Pellegrino MA, Reisfeld RA. Procedure for the selection of HLA xenoantisera for immunochemical characterization of HLA antigens. Transplantation Proceedings. 9: 601-4. PMID 194373  1
1977 Allison JP, Pellegrino MA, Ferrone S, Callahan GN, Reisfeld RA. Biologic and chemical characterization of HLA antigens in human serum. Journal of Immunology (Baltimore, Md. : 1950). 118: 1004-9. PMID 191523  1
1977 Allison JP, Pellegrino MA, Reisfeld RA, Ferrone S. An immune adsorption technique for analysis of antigenic determinants reacting with HLA antisera. Transplantation Proceedings. 9: 1691-3. PMID 74875  1
1977 Ferrone S, Mittal KK, Pellegrino MA, Allison JP, Reisfeld RA. Immunogenicity of HLA antigens purified from serum. Transplantation. 23: 7-15. PMID 65035  1
1976 Ferrone S, Pellegrino MA, Allison JP, Reisfeld RA. [Biological and chemical aspects of histocompatibility antigens in serum]. Haematologica. 61: 397-417. PMID 828605  1
1976 Reisfeld RA, Allison JP, Ferrone S, Pellegrino MA, Poulik MD. HL-A antigens in serum and urine: isolation, characterization, and immunogenic properties. Transplantation Proceedings. 8: 173-8. PMID 59439  1
1975 Prager MD, Ludden CM, Mandy WJ, Allison JP, Kitto GB. Endotoxin-stimulated immune response to modified lymphoma cells. Journal of the National Cancer Institute. 54: 773-5. PMID 1168264  1
1975 Callahan GN, Ferrone S, Allison JP, Reisfeld RA. Detection of H-2 antigens in serum. Transplantation. 20: 431-3. PMID 174256  1
1972 Allison JP, Davidson L, Gutierrez-Hartman A, Kitto GB. Insolubilization of L-asparaginase by covalent attachment to nylon tubing. Biochemical and Biophysical Research Communications. 47: 66-73. PMID 5027141  0.52
1971 Allison JP, Mandy WJ, Kitto GB. The substrate specificity of L-asparaginase from Alcaligenes eutrophus. Febs Letters. 14: 107-108. PMID 11945731 DOI: 10.1016/0014-5793(71)80112-6  1
Show low-probability matches.